Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy
Interventions: TR-701 di-sodium phosphate salt, TR-701 free acid phosphate; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperkalaemia
Interventions: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more

Conditions: Hot Flashes, Menopause, Vasomotor Symptoms
Interventions: Placebo, Omega-3, Yoga, Exercise, Usual Activity; Dietary Supplement · Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 355 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Restrictive Chronic Lung Allograft Dysfunction, Lung Transplant Rejection
Interventions: Pirfenidone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: Cysteamine, Placebo Oral Capsule; Drug
Lead sponsor: NovaBiotics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more

Conditions: Subclinical Hypothyroidism, Hypothyroxinemia, Pregnancy
Interventions: Levothyroxine, Placebo for Levothyroxine; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 1,203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more

Conditions: Night-eating Syndrome
Interventions: Melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: DOV 21, 947, Placebo; Drug
Lead sponsor: DOV Pharmaceutical, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 10
States / cities: Norwich, Connecticut • Springfield, Massachusetts • Cherry Hill, New Jersey + 7 more

Conditions: Healthy Volunteers
Interventions: GSBR-1290, Placebo; Drug · Other
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: ADHD
Interventions: Centanafadine, Methylphenidate, Lisdexamfetamine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Other Acute Postoperative Pain
Interventions: Indomethacin, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 1 more

Conditions: Healthy
Interventions: ABT-450, ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: HIV Infections
Interventions: Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 5
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole MR, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 99
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 96 more

Conditions: Multiple Myeloma
Interventions: Durvalumab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Healthy Volunteers
Interventions: Midazolam, Repaglinide, TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg, Lotrel® Capsules 10 mg/20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Liver Diseases, Liver Failure, Cirrhosis, Liver
Interventions: Commensal Bacteria Strains; Biological
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: ARQ 197, Erlotinib, Placebo; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Burbank, California • Santa Monica, California • Torrington, Connecticut + 14 more

Conditions: Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions: Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management; Drug · Other · Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Psychedelic Effects in Healthy Volunteers
Interventions: Pindolol, Placebo, Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atrial Fibrillation
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 162
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more

Conditions: Iron Deficiency Anemia
Interventions: Novel Medical Food; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Cardio-pulmonary Function
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

Melatonin Treatment for Night-Eating Syndrome

Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

Psilocybin Administration With 5-HT1a Blockade

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

A Trial to Evaluate the Safety and Tolerability of a Novel Medical Food for Management of Iron Deficiency Anemia

Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions